FDA nixes hydroxychloroquine, warns not to take with Gilead's Covid-fighting drug
Regulators on Monday withdrew emergency use authorization of a drug promoted by President Donald Trump for use against Covid-19 and warned that its combination with Gilead Sciences Inc.'s remdesivir could have side effects.
The Food and Drug Administration said a nonclinical laboratory study of Foster City-based Gilead's (NASDQ: GILD) remdesivir, which also has emergency use authorization, with chloroquine or hydroxychloroquine indicated "potential drug interactions." It recommended against administering…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: American Health | Biotechnology | COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Health Management | Hydroxychloroquine | Laboratory Medicine | Study | Trump | USA Health